Literature DB >> 21803030

Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches.

Elisabetta Mormone1, Joseph George, Natalia Nieto.   

Abstract

The pathogenesis of hepatic fibrosis involves significant deposition of fibrilar collagen and other extracellular matrix proteins. It is a rather dynamic process of wound healing in response to a variety of persistent liver injury caused by factors such as ethanol intake, viral infection, drugs, toxins, cholestasis, and metabolic disorders. Liver fibrosis distorts the hepatic architecture, decreases the number of endothelial cell fenestrations and causes portal hypertension. Key events are the activation and transformation of quiescent hepatic stellate cells into myofibroblast-like cells with the subsequent up-regulation of proteins such as α-smooth muscle actin, interstitial collagens, matrix metalloproteinases, tissue inhibitor of metalloproteinases, and proteoglycans. Oxidative stress is a major contributing factor to the onset of liver fibrosis and it is typically associated with a decrease in the antioxidant defense. Currently, there is no effective therapy for advanced liver fibrosis. In its early stages, liver fibrosis is reversible upon cessation of the causative agent. In this review, we discuss some aspects on the etiology of liver fibrosis, the cells involved, the molecular pathogenesis, and the current therapeutic approaches.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803030      PMCID: PMC3171510          DOI: 10.1016/j.cbi.2011.07.001

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  103 in total

Review 1.  Hepatoprotective effects of S-adenosyl-L-methionine against alcohol- and cytochrome P450 2E1-induced liver injury.

Authors:  Arthur I Cederbaum
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

2.  Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine.

Authors:  Semyon I Aleynik; Charles S Lieber
Journal:  Alcohol Alcohol       Date:  2003 May-Jun       Impact factor: 2.826

3.  Activation by acetaldehyde of the promoter of the mouse alpha2(I) collagen gene when transfected into rat activated stellate cells.

Authors:  F A Anania; J J Potter; L Rennie-Tankersley; E Mezey
Journal:  Arch Biochem Biophys       Date:  1996-07-15       Impact factor: 4.013

Review 4.  Liver fibrosis: from the bench to clinical targets.

Authors:  M Pinzani; K Rombouts
Journal:  Dig Liver Dis       Date:  2004-04       Impact factor: 4.088

5.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

6.  Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation.

Authors:  Yumei Fu; Shizhong Zheng; Jianguo Lin; Jan Ryerse; Anping Chen
Journal:  Mol Pharmacol       Date:  2007-11-15       Impact factor: 4.436

7.  Ascorbic acid concentrations in dimethylnitrosamine-induced hepatic fibrosis in rats.

Authors:  Joseph George
Journal:  Clin Chim Acta       Date:  2003-09       Impact factor: 3.786

8.  Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen.

Authors:  Yuan-Ping Han; Ling Zhou; Jiaohong Wang; Shigang Xiong; Warren L Garner; Samuel W French; Hidekazu Tsukamoto
Journal:  J Biol Chem       Date:  2003-11-14       Impact factor: 5.157

9.  Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms.

Authors:  Francisco Javier Cubero; Natalia Nieto
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

10.  Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats.

Authors:  Jin-Rong Xia; Nai-Feng Liu; Nai-Xun Zhu
Journal:  Int J Mol Sci       Date:  2008-04-24       Impact factor: 6.208

View more
  86 in total

1.  Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis.

Authors:  Maria Eduarda Rocha de França; Sura Wanessa Santos Rocha; Wilma Helena Oliveira; Laise Aline Santos; Anne Gabrielle Vasconcelos de Oliveira; Karla Patrícia Sousa Barbosa; Ana Karolina Santana Nunes; Gabriel Barros Rodrigues; Deniele Bezerra Lós; Christina Alves Peixoto
Journal:  Inflammopharmacology       Date:  2017-04-13       Impact factor: 4.473

2.  Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma.

Authors:  N E El-Bassiouni; M M F Nosseir; M E Madkour; M M K Zoheiry; I W Bekheit; R A Ibrahim; I M Ibrahim; A E El Bassiouny
Journal:  Mol Biol Rep       Date:  2012-02-09       Impact factor: 2.316

Review 3.  Zebrafish models of human liver development and disease.

Authors:  Benjamin J Wilkins; Michael Pack
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

4.  Adipose tissue-liver axis in alcoholic liver disease.

Authors:  Zhi-Gang Wang; Xiao-Bing Dou; Zhan-Xiang Zhou; Zhen-Yuan Song
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 5.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 6.  Hepatic stellate cells--the pericytes in the liver.

Authors:  Claus Hellerbrand
Journal:  Pflugers Arch       Date:  2013-01-05       Impact factor: 3.657

7.  Kinetin inhibits proliferation of hepatic stellate cells by interrupting cell cycle and induces apoptosis by down-regulating ratio of Bcl-2/Bax.

Authors:  Zhen-Gang Zhang; Jie Zou; Ying Huang; Liang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

8.  Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids.

Authors:  Lirui Wang; Phillipp Hartmann; Michael Haimerl; Sai P Bathena; Christopher Sjöwall; Sven Almer; Yazen Alnouti; Alan F Hofmann; Bernd Schnabl
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

Review 9.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 10.  Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.

Authors:  Giuseppina Palladini; Andrea Ferrigno; Plinio Richelmi; Stefano Perlini; Mariapia Vairetti
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.